Abstract 402P
Background
Immuno-checkpoint inhibitors (ICIs) has become standard second line therapy for advanced NSCLC patients (pts). However, early progression remained a major challenge with ICIs monotherapy. The synergetic effect of ICIs plus chemotherapy has been demonstrated in first line setting. Our study aims to explore if the combination of a PD-1 inhibitor with chemotherapy can provide additional clinical benefits in previously treated advanced NSCLC pts.
Methods
Advanced NSCLC pts who had failed standard platinum doublet without receiving any ICIs before would be enrolled in this single-arm phase II study. EGFR/ALK positive pts must be TKIs failure or intolerable. Eligible pts would receive docetaxel (75mg/m2, day 1) plus sintilimab (200mg, day 3) every 3 weeks for 4-6 cycles followed by sintilimab maintenance until disease progression, unacceptable toxicity, or up to 2 years. The primary end point is progression-free survival (PFS) per RECIST v1.1. Secondary end points included overall response rate (ORR), duration of response (DOR), overall survival, and safety.
Results
From 10/2019 to 4/2020, 28 pts were enrolled. Most were male (75%) and adenocarcinoma (85.7%). 21.4% pts had brain metastasis at baseline. Median follow-up was 5.1m (range 2.4-8.1) as of data cut-off (6/17/2020). 42.9% (12/28) pts were still on study treatment. PFS data was immature with only 35.7% (10/28) events. Estimated median PFS was 5.5m (95%CI 3.6-NE). Of the 25 evaluable pts, ORR is 24% (95%CI 9%, 45%), DCR is 92% (95%CI 74%, 99%). Median DOR was not reached (95% 1.28m, NA). Overall, 60.7% (17/28) pts had experienced treatment emergent adverse events (TEAEs), including 17.9% (5/28) grade 3-4 cases. No AEs led to treatment discontinuation or death. The most common TEAEs were leukopenia (50%), neutropenia (28.6%), alopecia (17.9%), lymphopenia (14.3%) and fatigue (14.3%).
Conclusions
This first report of a PD-1 inhibitor plus chemotherapy in advanced Chinese NSCLC pts who had failed first-line chemotherapy showed encouraging efficacy and tolerable safety profile. Enrollment is ongoing and more data will be presented.
Clinical trial identification
ChiCTR1900027634.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Innovent Biologics, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - Factors affecting duration of admission in the palliative medicine ward of a tertiary cancer hospital: A pilot, investigator initiated, review of services
Presenter: Rahul D. Arora
Session: e-Poster Display Session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session